Tenders of Aok Rheinland Pfalz Saarland Die Gesundheitskasse
Tenders of Aok Rheinland Pfalz Saarland Die Gesundheitskasse
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Healthcare and Medicine
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products with the active ingredient Tamoxifen (l02ba01) as part of a so-called open-house model.
Closing Date31 Aug 2025
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Healthcare and Medicine
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 Sgb V for medicinal products with the active ingredient bimatoprost (s01ee03) as part of a so-called open-house model.
Closing Date31 May 2025
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Healthcare and Medicine
Germany
Germany – Pharmaceutical Products – Abschluss Nicht Exklusiver Rabattverträge Gemäß §§ 130a Abs. 8/130c Abs. 1 Sgb V Zu Arzneimitteln Mit Dem Wirkstoff Haloperidol (n05ad01) Im Rahmen Eines Sogenannten Open-house-modells.
Closing Date31 Jan 2026
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Germany
Germany – Pharmaceutical Products – Abschluss Nicht Exklusiver Rabattverträge Gemäß §§ 130a Abs. 8/130c Abs. 1 Sgb V Zu Arzneimitteln Mit Dem Wirkstoff Irbesartan Und Hydrochlorothiazid (c09da24) Im Rahmen Eines Sogenannten Open-house-modells.
Closing Date31 Jul 2026
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Healthcare and Medicine
Germany
Conclusion of non-exclusive discount agreements in accordance with §§ 130a paragraph 8/130c paragraph 1 Sgb V for drugs with the active ingredient fluorouracil (d11af05) as part of a so-called open-house model.
Closing Date30 Jun 2025
Tender AmountRefer Documents
AOK Rheinland Pfalz Saarland Die Gesundheitskasse Tender
Germany
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products with the active ingredient dabigatran (b01ae07) as part of a so-called open-house model.
Closing Date30 Nov 2025
Tender AmountRefer Documents
21-30 of 256 active Tenders